Abstract:【Objective】To investigate the inhibition proliferation effect of the targeting IL18-EGF fused protein created by ourselves on human hepatic carcinoma cell lines SMMC-7721 cells in vivo and the inhibitory rate in nude mice model so as to seeking a new way for biological therapy of human hepatic carcinoma.【Methods】 SMMC-7721 cells were subcutaneously injected into the right flank of Balb/c nude mice.The mice with established SMMC-7721 xenograft were randomized into three groups of treatment:IL18-EGF,rhIL18 and NS blank group.Tu-mor-bearing mice were treated with peritumoral subcutaneously injection of NK-92 cells irradiated with X-ray fol-lowed by peritumoral subcutaneously injection of the three groups.The next morning after the last dosage,all mice were sacrificed and the tumor masses and mouse organs were completely dissected for further usage.【Results】Be-fore the end of therapy,we found volume of xenograft tumor was(0.063±0.030) mm3 in IL18-EGF group,(0.212± 0.037) mm3 in rhIL18 group,and(0.432±0.030) mm3 in control group respectively.Compared to control,SMMC-7721 xenograft growth in Balb/c nude mice was markedly inhibited with peritumoral injection of IL18-EGF or rhIL18(P <0.01).Furthermore,the inhibitory effect of IL18-EGF on SMMC-7721 growth in vivo was more profound than that of rhIL18(P <0.05).Meanwhile,more tumor cells were arrested in G1 phase in IL18-EGF group(96.11%± 1.51%),compared to rhIL18 group [(81.3%±2.02%),P <0.05] as well as to control [(72.18%±0.46%),P <0.01].The difference on the percentage of G1 phase between rhIL18 group and control was also significant(P <0.05).The per-centages of S phase in IL18-EGF group,rhIL18 group and control were(3.69%±0.41%),(16.51%±1.25%),and(23.85%±1.36%),respectively(IL18-EGF vs rhIL18:P <0.01;IL18-EGF vs control:P <0.01;IL18 vs control:P < 0.05).Tumor spontaneous apoptotic rates in IL18-EGF,rhIL18 and control group were(28.05%±3.89%)(P <0.05,compared to control),(25.48%±5.46%)(P <0.05,compared to control) and(7.10%±1.13%),respectively.And there was still not significant difference between IL18-EGF and rhIL18 group on spontaneous apoptosis induction.No sig-nificant difference was observed on pathologic features of SMMC-7721 xenograft grown in Balb/c nude mice treated with IL18-EGF,rhIL18 and control,respectively.【Conclusions】Subcutaneous injection of IL18-EGF and NK cells adjacent to tumor significantly inhibited the growth of SMMC-7721 transplantation tumor which suggested that IL18-EGF fused protein owned the effect of the antineoplastic activity in vivo and can be an effective means in the biological therapy.

Experimental Study of Targeting Therapy of Breast Cancer with 131I-Labeled Epidermal Growth Factor

Experimental Research into the Inhibitory Effect of 131I-Recombinant Human Epidermal Growth Factor on the Growth of Breast Cancer in Vivo

Radiobiological Effect of 131I Radiolabeled Recombinant Human Epidermal Growth Factor on Nude Mice with Human Breast Cancer

131I-recombinant human EGF has antitumor effects against MCF-7 human breast cancer xenografts with low levels of EGFR

Evaluation of Therapeutic Effectiveness Of131i-Antiegfr-bsa-pcl in a Mouse Model of Colorectal Cancer

Evaluation of the internal therapeutic effectiveness of 131I-antiEGFR-BSA-PCL in nude mice with colorectal cancer

Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer.

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

[Experimental Study of Radioimmunotherapy for Xenograft of Human Esophageal Carcinoma].

Antitumor effect of 131 I-labeled anti-VEGFR2 targeted nanoparticles in anaplastic thyroid carcinoma mouse models

The Superparamagnetic Nanoparticles Carrying the E1A Gene Enhance the Radiosensitivity of Human Cervical Carcinoma in Nude Mice

Radionuclide therapy using 131 I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression

The experimental study of radioimmunoimaging and radioimmunotherapy using ~(131)I-labeled anti-progastrin-releasing peptide_((31-98)) monoclonal antibody E-B_5

An Experimental Study On Targeted Therapy Of Radioiodinated Cyclic Crgd Peptide On Melanoma Bearing Mice

Effect of targeting IL18-EGF fused protein on the antineoplastic activity in vivo

Gefitinib Enhances Radiotherapeutic Effects of 131 I–hEGF Targeted to EGFR by Increasing Tumor Uptake of Hegf in Tumor Xenografts

Local Radioimmunotherapy of Breast Cancer-Bearing Nude Mice Using Anti-Cea Monoclonal Antibody C50 Labeled with 131I

Biodistribution of 131 I-Herceptin in Breast Cancer Xenograft

Radioimmunoimaging and Biodistribution of 131I-Herceptin in Breast Cancer Xenograft BALB/c-neu Mousse

Effect of (131)I gelatin microspheres on hepatocellular carcinoma in nude mice and its distribution after intratumoral injection.

[Effect of 131I-Labeled Recombinant Human Tumor Necrosis Factor-Alpha on the Nude Mice Bearing Human Hepatoma].